Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 6/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 6/20 | 0.84 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.84 |
| ▸ | PTGFR | P43088 | 4/20 | 0.84 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | PTGIR | P43119 | 2/20 | 0.60 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.60 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.60 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nocloprost SCHEMBL1554645 | 1.00 | PTGER3 (0.84) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| Nocloprost SCHEMBL3873408 | 1.00 | PTGER3 (0.84) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| Nocloprost SCHEMBL9847683 | 1.00 | PTGER3 (0.84) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| Nocloprost SCHEMBL1554648 | 1.00 | PTGER3 (0.84) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| Nocloprost SCHEMBL10803435 | 1.00 | PTGER3 (0.84) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| Nocloprost SCHEMBL9480879 | 0.95 | PTGER3 (0.76) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| SCHEMBL11484121 | 0.91 | PTGFR (1.00) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| SCHEMBL3366405 | 0.91 | PTGFR (1.00) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| SCHEMBL10774699 | 0.91 | PTGFR (0.68) | PTGER3TBXA2RPTGER1PTGFRPTGER2 | |
| SCHEMBL9481875 | 0.90 | PTGFR (0.68) | PTGER3TBXA2RPTGER1PTGFRPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220401487-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2022-12-22 | — | — | US | claimed |
| US-11413309-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2022-08-16 | — | — | US | claimed |
| US-20200172870-A1 | CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE | FATE THERAPEUTICS INC (US) | 2020-06-04 | — | — | US | claimed |
| US-20190282618-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2019-09-19 | — | — | US | claimed |
| EP-3533445-A1 | COMPOSITIONS COMPRISING CYCLIC AMP ENHANCERS AND/OR EP LIGANDS, AND METHODS OF PREPARING AND USING THE SAME | Fate Therapeutics, Inc. (US) | 2019-09-04 | — | — | EP | claimed |
| US-20190119635-A1 | MODULATION OF T LYMPHOCYTES | FATE THERAPEUTICS, INC. | 2019-04-25 | — | — | US | claimed |
| EP-3405568-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | Fate Therapeutics, Inc. (US) | 2018-11-28 | — | — | EP | claimed |
| US-20180112180-A1 | CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE | FATE THERAPEUTICS, INC. | 2018-04-26 | — | — | US | claimed |
| EP-3292200-A1 | MODULATION OF T LYMPHOCYTES | Fate Therapeutics, Inc. (US) | 2018-03-14 | — | — | EP | claimed |
| EP-3278808-A1 | IMPROVED HEMATOPOIETIC STEM AND PROGENITOR CELL THERAPY | Fate Therapeutics, Inc. (US) | 2018-02-07 | — | — | EP | claimed |
| EP-0664707-A1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA. | ALCON LAB INC (US) | 1995-08-02 | — | — | EP | claimed |
| WO-1994012186-A1 | PROSTAGLANDIN DERIVATIVE HAVING RADIOPROTECTIVE EFFECTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-06-09 | — | — | WO | claimed |
| WO-1994008585-A1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1994-04-28 | — | — | WO | claimed |
| WO-1993005785-A1 | COMBINATION PHARMACEUTICAL PREPARATIONS CONTAINING A NON-STEROIDAL ANTI-INFLAMMATORY AGENT AND NOCLOPROST | SCHERING AG (DE) | 1993-04-01 | — | — | WO | claimed |
| EP-0243369-B1 | 9-HALOGEN PROSTAGLANDINE CLATHRATES AND UTILIZATION THEREOF AS DRUGS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-03-18 | — | — | EP | claimed |
| US-5095010-A | ANTIGESTAGENS, GLUCOCORTICOIDS AND PROSTAGLANDINS FOR INDUCTION OF LABOR OR FOR TERMINATION OF PREGNANCY | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-03-10 | — | — | US | claimed |
| US-5079259-A | PHARMACEUTICALLY ACTIVE 9-CHLOROPROSTAGLANDINS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-01-07 | — | — | US | claimed |
| US-5047525-A | With cyclodextrin ty | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-10 | — | — | US | claimed |
| US-4626531-A | Prostaglandins and antigestagens for induction of labor and for abortion | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-12-02 | — | — | US | claimed |
| EP-0030377-B1 | 9-CHLORO-PROSTAGLANDIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE AS MEDICINES | SCHERING AKTIENGESELLSCHAFT (DE) | 1984-02-22 | — | — | EP | claimed |